Milestone Pharmaceuticals (MIST) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Milestone Pharmaceuticals has announced its second quarter financial results, revealing a cash reserve sufficient to fund operations through 2026 and the FDA’s acceptance of their new drug, CARDAMYST™, for PSVT, with a potential launch in 2025. Additionally, preparations for a Phase 3 study in AFib-RVR are underway, reflecting the company’s ongoing strategic advancements in its drug development pipeline.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.
